1 Protein synthesis inhibitors (e.g. cycloheximide) prevent cells from entering mitosis, 2 suggesting that cell cycle progression requires protein synthesis until right before mitotic 3 entry. However, cycloheximide is also known to activate p38 MAPK, which can delay 4 mitotic entry through a G2/M checkpoint. Here we asked whether checkpoint activation 5 or a requirement for protein synthesis is responsible for the cycloheximide effect. We 6 found that p38 inhibitors prevent cycloheximide-treated cells from arresting in G2 phase, 7and that G2 duration is normal in about half of these cells. The Wee1/Myt1 inhibitor 8 PD0166285 also prevents cycloheximide from blocking mitotic entry, raising the 9 possibility that Wee1 and/or Myt1 mediate the cycloheximide-induced G2 arrest. Thus, 10 the ultimate trigger for mitotic entry appears not to be the continued synthesis of mitotic 11 cyclins or other proteins. However, M-phase progression was delayed in cycloheximide-12 plus-kinase-inhibitor-treated cells, emphasizing the different requirements of protein 13 synthesis for timely entry and completion of mitosis. 14 15 Impact statement (30 words): 16 Cycloheximide arrests cells in G2 phase due to activation of p38 MAPK, not inhibition of 17 protein synthesis, arguing that protein synthesis in G2 phase is not required for mitotic 18 entry. 19 4 end of G2 phase (12, 22). Cdk1-cyclin B1 then translocates from the cytoplasm to the 42 nucleus just prior to nuclear envelope breakdown (16,(23)(24)(25)(26). 43The final increase in cyclin B1-Cdk1 activity, and decrease in PP2A-B55 activity, is 44 thought to be due to the flipping of two bistable switches. Two feedback loops, a double-45 negative feedback loop involving the Cdk1-inhibitory kinases Wee1/Myt1 and a positive 46 feedback loop involving the Cdk1-activating phosphatase Cdc25, keep Cdk1 activity low 47